Table 3.
The expression of Tenascin-C and α-SMA in patients with COPD, smokers (S) and non-smokers (NS)
| COPD | S | NS | |
|---|---|---|---|
| Tenascin C (Tn-C) | |||
| Number of acceptable biopsies | 20 | 12 | 14 |
| Subjects expressing Tn-C only in basal epithelial cells and basal membrane, Tn-C (a) | 5 (25%) | 9 (75%) | 11 (79%) |
| Subjects expressing Tn-C as Tn-C (a) plus the stroma underneath basement membrane, Tn-C (b) | 10 (50%) | 2 (17%) | 3 (21%) |
| Subjects expressing Tn-C as Tn-C (b) plus wider expression within connective tissue, Tn-C (c) | 5 (25%) | 1 (8%) | 0 (0%) |
| α-SMA | |||
| Number of acceptable biopsies | 18 | 13 | 12 |
| Subjects with no cells expressing α-SMA, SMA (a) | 3 (17%) | 7 (54%) | 7 (59%) |
| Subjects with 1-5 cells expressing α-SMA, SMA (b) | 6 (33%) | 2 (15%) | 3 (25%) |
| Subjects with 5-10 cells expressing α-SMA, SMA© | 4 (22%) | 3 (23%) | 1 (8%) |
| Subjects with >10 cells expressing α-SMA, SMA (d) | 5 (28%) | 1 (8%) | 1 (8%) |